Activin receptor antagonists for cancer-related anemia and bone disease. - Wikidata - wikimedia - TriplyDB

Activin receptor antagonists for cancer-related anemia and bone disease.

Activin receptor antagonists for cancer-related anemia and bone disease.

http://www.wikidata.org/entity/Q38057813

about

Activin receptor-like kinases: a diverse family playing an important role in cancer Targeted treatments of bone metastases in patients with lung cancer Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice Follistatin is induced by ionizing radiation and potentially predictive of radiosensitivity in radiation-induced fibrosis patient derived fibroblasts.Adult-specific systemic over-expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII.Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.Virtual High-Throughput Screening To Identify Novel Activin Antagonists.Utilizing BMP-2 muteins for treatment of multiple myeloma Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin β3 via SMAD2/3 signaling Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.Recent advances: osteoporosis in the "oldest old".Anemia in malignancies: pathogenetic and diagnostic considerations.The ESA scenario gets complex: from biosimilar epoetins to activin traps.Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects.Experimental and investigational therapies for chemotherapy-induced anemia.Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.Investigational therapies for renal disease-induced anemia.A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.Emerging treatment approaches for myeloma-related bone disease.Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy.Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report.Innate immune system activation in zebrafish and cellular models of Diamond Blackfan Anemia.Characterization of an Animal Model to Study Risk Factors and New Therapies for the Cardiorenal Syndrome, a Major Health Issue in Our Aging Population.

P2860

Q28066886-2A864FF2-448C-4AFB-A037-17C74E5E9A7D Q33759713-88EB28EC-A55C-42EE-8667-D626796B4D9A Q33827405-12B4AB19-3BBB-48EA-BB9D-C0B4DEA63B02 Q34771518-A56DBB8B-6166-49D7-AA24-05B65091FE07 Q35035034-DCC2A4F1-509F-415F-80A6-F1D4A5ABC9C9 Q35035999-CAAAA43A-2F94-4914-93D0-380146830555 Q35105275-D5C5023E-CEB7-4097-B58F-9DC6D2209A98 Q36153838-A08D38BA-0715-4BDA-B9C7-7324C2C332C4 Q36256670-F3724881-A269-4006-8F19-0CCFA509B96E Q36367921-276C404E-8F44-4786-9DF2-E35F70A9C8E5 Q36544657-2D9954EE-18F1-4280-ACE9-BB58B84096F1 Q36615063-D267E44F-DB14-4640-8E0F-0F9E3CE330CE Q37397495-D842F4F2-8A47-42CB-AE78-4422D64C6AB2 Q37673351-E7EF9019-B012-439D-944B-ECA9DE18793E Q38129287-C19144B9-9D07-4409-B08A-B25EDE714CD5 Q38199176-B4BE6BCA-4FBA-4D19-8549-D150037D49CD Q38205752-9A6421E4-20A3-4308-B935-A3E5D9DB8C50 Q38336989-C1E04CC4-0BD2-4AC4-933D-C3AF23EF1D5E Q38584639-9858D831-C4C6-41BA-B62C-EFE4FA85C506 Q38613789-77C00142-1F04-429C-893E-9A3BF9701761 Q38819455-E52DEA5E-6EE0-429F-847B-85D19EF0F83B Q38924940-9FEA02E0-8B3D-4894-A733-6E71250A3A2F Q39090721-C3802501-3082-4F5E-81D0-922D39328E3B Q40369700-E1D01E10-4B57-4719-90EE-B263B4838D82 Q51498595-42A2F71C-7FBC-4FC2-8CC2-86A274926F9F Q51731314-E00ED3E2-6DBB-44BA-8B89-0A7861EC11CD Q51807865-78057817-B71C-487B-B328-C7F51CF6EBF0

P2860

Activin receptor antagonists for cancer-related anemia and bone disease.

http://www.wikidata.org/entity/Q38057813

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Activin receptor antagonists for cancer-related anemia and bone disease.

@en

type

label

Activin receptor antagonists for cancer-related anemia and bone disease.

@en

prefLabel

Activin receptor antagonists for cancer-related anemia and bone disease.

@en

P1433

Q38057813-E8696BBF-F2A5-4DB5-B46C-80A4ECC0E36A

P1476

Q38057813-71579AC4-DB1F-4B7A-B96E-17008F0F5115

P2093

Q38057813-561E3420-E8DE-455E-B9D1-9C077827C981

Q38057813-8CC5AFC6-7EF6-4D23-AF6D-112395C07606

Q38057813-9E28705C-E8A2-4B8E-B639-43F553F601EF

Q38057813-C1406FC0-B9D0-4C0C-B888-FEB45215B24E

Q38057813-D065923F-5BD6-4750-BFE7-7AFAF27CC328

Q38057813-D0AD26EB-B086-46F7-8A00-0B3C934058AE

Q38057813-D5A3E439-C7DC-49BB-8704-1205B58596A3

Q38057813-F054CF28-7D7D-47EA-AF04-C84AAC7401A6

Q38057813-F804FEAE-B860-4741-B4C1-AF4B8D3DF3E6

P2860

Q38057813-0402F855-78A7-4668-9ABC-5417436413C8

Q38057813-051B6E37-F3B8-4038-8086-1FBCBA0B0F4B

Q38057813-0B0CD180-6F59-4E9E-B181-A4E398CF0D27

Q38057813-0FA56453-C3C5-4608-8996-4EBE1492E679

Q38057813-0FD085EF-3D14-450B-8538-4F5CDDEA3670

Q38057813-1807A2E5-4C24-4B4A-83DE-A36A6E5F4AEE

Q38057813-1AEB7AEA-0203-4201-AB15-90D188777EAB

Q38057813-1C75CD2D-E648-48CC-940D-E5CC40E687B2

Q38057813-1E2E3242-B1B6-476A-862C-6D8FC5E0FA72

Q38057813-1F4C420A-2696-42C1-A764-6CE088880BD7

P304

Q38057813-BF2D6DF2-BB50-4F9A-97CD-F8D165035EDD

P31

Q38057813-4E0E806C-0338-446E-9388-85F00E2E357C

P356

Q38057813-2D45421C-ECAF-42FC-AF99-E6E3A1F32EBA

P407

Q38057813-7707EBB6-83EB-4AE7-B024-BCD5D8C217D3

P433

Q38057813-70DF19BC-68BD-4301-A424-C1DDD35360F9

P478

Q38057813-E300B836-0AD2-4955-A2E2-D71E34E85FBE

P577

Q38057813-1320D68E-09F1-40B3-A492-456EBD935613

P698

Q38057813-E3F3A5C7-209B-48F3-9525-389CBCD0C36E

P356

13543784.2013.738666

P1433

Expert Opinion on Investigational Drugs

P1476

Activin receptor antagonists for cancer-related anemia and bone disease.

@en

P2093

Abderrahmane Laadem

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Haralambos Raftopoulos

http://www.w3.org/2001/XMLSchema#string

Madhurima Anne

http://www.w3.org/2001/XMLSchema#string

Mark J Alexander

http://www.w3.org/2001/XMLSchema#string

Matthew L Sherman

http://www.w3.org/2001/XMLSchema#string

Scott Z Fields

http://www.w3.org/2001/XMLSchema#string

Shiroo Parshad

http://www.w3.org/2001/XMLSchema#string

Victoria Sung

http://www.w3.org/2001/XMLSchema#string

P2860

Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling

Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7

Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4

Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells

The role of activin a in regulation of hemopoiesis

ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma

Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin

The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding

Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family

P304

87-101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2013.738666

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23127248

http://www.w3.org/2001/XMLSchema#string